Skip to main content
Clinical Trials/NCT05968794
NCT05968794
Recruiting
Not Applicable

The Effectiveness of Cerclage for the Reduction of Extreme Preterm Birth and Perinatal Mortality in Twin Pregnancies With a Short Cervix or Dilatation

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)13 sites in 2 countries238 target enrollmentMay 15, 2023
ConditionsPreterm Birth

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Preterm Birth
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Enrollment
238
Locations
13
Primary Endpoint
Rate of extreme preterm birth
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The goal of this clinical trial is to assess the effectiveness of a cerclage in women with a twin pregnancy with a midpregnancy short cervix or cervical dilatation compared to standard treatment (no cerclage) in the prevention of extreme preterm birth < 28 weeks of gestational age.

The main question it aims to answer is: What is the effectiveness of a cerclage in women with a twin pregnancy with a midpregnancy short cervix or cervical dilatation compared to standard treatment (no cerclage) in the prevention of extreme preterm birth < 28 weeks of gestational age?

Participants will be randomly assigned to the intervention (cerclage) or comparison (no cerclage) group.

Detailed Description

Rationale: In the Netherlands, 250 women with a twin pregnancy deliver at \< 28 weeks per year, resulting in 157 perinatal deaths. A vaginal cerclage could be an effective surgical method to reduce cervical insufficiency and with that preterm birth, but the evidence regarding its effectiveness on extreme preterm birth and (long term) neonatal outcome is lacking. Objective: To assess the effectiveness of a cerclage in women with a twin pregnancy with a midpregnancy short cervix or cervical dilatation compared to standard treatment (no cerclage) in the prevention of extreme preterm birth \< 28 weeks of gestational age. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: A vaginal cerclage is a minor and safe surgical procedure commonly performed in singleton pregnancies with a short cervix and a previous preterm birth in all the participating centers, thus there is experience in the participating hospitals. The results of this study will show whether a vaginal cerclage reduces extreme preterm birth in women with twin pregnancy and a short cervix, and its accompanying perinatal complications. If proven effective, the implementation of this intervention will have a huge impact on the lifelong health of these children and their families.

Registry
clinicaltrials.gov
Start Date
May 15, 2023
End Date
December 1, 2028
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Martijn A. Oudijk, MD, PhD

Prof.dr.

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Eligibility Criteria

Inclusion Criteria

  • Women (\> 16 years of age) with a twin pregnancy and:
  • an asymptomatic short cervix at routine ultrasound investigation (below 24 weeks of gestation) OR
  • cervical dilatation (below 24 weeks of gestation)

Exclusion Criteria

  • Women with a mono-amniotic twin pregnancy
  • Women with twin pregnancy in which one or both children are diagnosed with a major structural, congenital or chromosomal abnormality that is likely to influence the composite adverse neonatal outcome.
  • Women with dilatation of the cervix and signs of clinical intra-uterine infection, defined by the presence of fever ≥ 38 degrees Celsius.
  • Women with overt symptoms of preterm labour at time of measurement of short cervix (regular contractions, PPROM, recurrent blood loss).
  • Women with a placenta previa, defined as a placenta position covering the internal ostium of the cervix.
  • Women who do not master the Dutch of English language and therefore not able to give written consent

Outcomes

Primary Outcomes

Rate of extreme preterm birth

Time Frame: <28 weeks of gestation

Secondary Outcomes

  • Days in NICU(Up to 3 months corrected age)
  • Rate of maternal outcomes(Up to 3 months corrected age)
  • Number of neonates with bronchopulmonary dysplasia(Up to 3 months corrected age)
  • Number of neonates with periventricular leucomalacia > grade 1(Up to 3 months corrected age)
  • Number of neonates with intraventricular hemorrhage > grade 2(Up to 3 months corrected age)
  • Days on ventilation support(Up to 3 months corrected age)
  • Rate of Premature rupture of membranes(Up to 42 weeks of pregnancy)
  • Gestational age at delivery(At delivery)
  • Rate of Preterm birth(<24, <32, <34 and <37 weeks)
  • Adverse neonatal outcome(Up to 3 months corrected age)
  • Number of neonates with necrotizing enterocolitis > stage 2(Up to 3 months corrected age)
  • Number of neonates with proven sepsis(Up to 3 months corrected age)
  • Maternal quality of life assessed by the 'European Quality of life 5-Dimension 5-Level' score(Up to 3 months corrected age)
  • Number of neonates with retinopathy of prematurity > stage 2(Up to 3 months corrected age)
  • Perinatal death(Up to 3 months corrected age)

Study Sites (13)

Loading locations...

Similar Trials